193 related articles for article (PubMed ID: 30281138)
21. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
22. Reversible BRAF inhibitor-induced acute exudative paraneoplastic polymorphous vitelliform maculopathy.
Samalia P; Niederer R
N Z Med J; 2021 Aug; 134(1540):89-92. PubMed ID: 34482393
[No Abstract] [Full Text] [Related]
23. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
24. Second primary melanomas on treatment with vemurafenib.
Dalle S; Poulalhon N; Debarbieux S; Thomas L
Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
[No Abstract] [Full Text] [Related]
25. N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.
Harada K; Kato Y; Maeda T; Yoshida M; Irisawa R; Nagao T; Tsuboi R
J Dermatol; 2017 May; 44(5):e101-e102. PubMed ID: 27790745
[No Abstract] [Full Text] [Related]
26. Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib.
Jovic A; Tiodorovic D; Popovic D; Vidovic N; Zlatanovic Z; Cekic S; Kocic H; Damiani G
Eur J Dermatol; 2021 Apr; 31(2):279-280. PubMed ID: 34001482
[No Abstract] [Full Text] [Related]
27. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
29. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
31. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
32. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
33. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
34. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
35. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
36. Facial spiny follicular hyperkeratosis induced by vemurafenib.
Nieto Rodríguez D; Gómez Fernández C; Rueda Carnero JM
J Dermatol; 2018 Feb; 45(2):e43-e44. PubMed ID: 28971523
[No Abstract] [Full Text] [Related]
37. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
38. Eosinophilic pustular folliculitis induced by carbamazepine.
Mizoguchi S; Setoyama M; Higashi Y; Hozumi H; Kanzaki T
J Am Acad Dermatol; 1998 Apr; 38(4):641-3. PubMed ID: 9555813
[No Abstract] [Full Text] [Related]
39. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
40. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]